Click to view this email in a browser
Forward this message to a colleague
We are pleased to share with you the latest Global Fund Private Sector Delegation (PSD) newsletter covering news and information on the PSD, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and its Board.
This edition of the PSD Newsletter contains
June 16 - 19 | Colombo, Sri Lanka
The first meeting since the appointment of new Executive Director, Dr. Mark Dybul, and the final meeting under the leadership of Board Chair Simon Bland, and Vice-Chair Mphu Ramatlapeng, the June Global Fund Board meeting marked major changes in Board leadership. Bland and Ramatlapeng stepped down from their respective roles at the close of the Board meeting.
The PSD has selected new leadership to represent the delegation at the Global Fund Board. Paul Schaper, Executive Director Global Public Policy, Merck, was elected as Board Member, for a term beginning on June 20, 2013 and Renuka Gadde, Vice President, Global Health, BD, was reelected to continue serving as Alternate Board Member. Schaper brings to the role over two decades of global health policy, disease prevention and treatment experience. Gadde will draw on her experience in her first term as Alternate Board Member as well as her work with BD’s global health activities and partnerships. Read the new PSD Leadership's exclusive interviews here.
GBCHealth was formally re-appointed for a new three-year term as the Global Fund Private Sector Delegation’s Focal Point after a competitive proposal process conducted in early 2013. The new term began at the close of the recent Global Fund Board meeting in June 2013. Over the next three years, GBCHealth will facilitate the PSD’s participation in activities that bring the private sector’s voice to Global Fund Board policy and strategy, including a research project to value private sector non-cash contributions to the Global Fund, a toolkit to increase country-level private sector engagement, and participation in key Board meetings, retreats and forums. GBCHealth’s Whitney White, who has served as Interim Focal Point since mid-2012, will continue in the Focal Point role in the new term. Read more about GBCHealth’s appointment here.
In early 2013, the Global Fund launched the transition to the new funding model, approved by the Board in late 2012. The new model replaces the previous Rounds-based system and aims to simplify grant application and disbursement processes while improving measurable results.
With an ambitious target of $15 billion needed to effectively fund the fight against the three diseases, the Global Fund has been working with donors to ensure a successful Voluntary 4th Replenishment. To be launched in Q3/Q4 of 2013, the Replenishment will be chaired by the United Nations Secretary-General, Ban Ki-moon, with several co-chairs leading replenishment efforts among different donor communities. Four different groups or pillars were identified as targets for the Replenishment: traditional donors, emerging economies, domestic financing from implementing countries, and the private sector. President Goodluck Jonathan of Nigeria was the first appointed Co-Chair, announced in April 2013.
May 15 - 17, 2013 | New York City
When it comes to investing in a healthier future, “it’s now or never,” said the Global Fund’s new Executive Director, Mark Dybul, speaking at this year’s GBCHealth Annual Conference. With a strong focus on the private sector’s role in supporting the Global Fund and the health-related MDGs, the event featured 25 content-rich sessions, 70 speakers and more than 600 attendees from the private sector, governments, non-profits and foundations.
PSD companies, including AbbVie, Abt Associates, Access Bank, Anglo American, Bayer, BD, Chevron, Eli Lilly, Merck, Mylan, Novartis, (RED), Sumitomo Chemical and Vestergaard Frandsen attended the event as speakers, sponsors and participants. Key representatives from the Global Fund Secretariat, the then-Board Chair and Vice-Chair Simon Bland and Mphu Ramatlapeng, and Board leadership from the U.S., Sweden, and Developing Country NGOs, were also in attendance.
The PSD launched a project to quantify financial, non-monetary and in-kind contributions by the private sector to the Global Fund to arrive at a more comprehensive estimate of the private sector’s support. While financial contributions made to the Global Fund are recorded, there is currently no agreed methodology in place for valuing non-cash contributions, such as grant co-investments, no-profit/no-loss commodity supply, pro-bono services, research and development, and more. Abt Associates and TropMed Pharma, on behalf of the PSD and with support from GBCHealth, have been leading an initiative to quantify these contributions. A final report of the project’s findings will be released prior to the Global Fund’s Replenishment pledging Conference to be held later this year.
With more than 25 years of experience in global health, Mark Dybul brings to his new role as the Global Fund’s Executive Director an ambitious vision and a strong background in successfully creating and implementing public-private partnerships.
Read the recently-released Global Fund PSD 2012 Annual Report to learn about the private sector's contributions to major developments at the Global Fund last year, including the selection of a new Executive Director selection process, the development of the new funding model and implementation of a comprehensive reform agenda. Read the full report here.
Despite being a treatable and preventable disease, malaria claimed 660,000 lives in 2010, and 91% of these deaths were in the African continent. Since 2001, Sanofi, an integrated healthcare company focused on patients’ needs, has been implementing a comprehensive program against malaria in Africa focused on:
Read more about Sanofi's Impact Malaria program here.
El Salvador, Myanmar and Zimbabwe
Three early applicants submitted five concept notes as the first countries to apply for grants under the new funding model. These grant applications were approved in June 2013 for a total amount of $622 million.
Under the new model, countries can apply for two types of funding: indicative and incentive funding. Indicative funding is for a country's priority interventions, and each country receives a needs-based range at the start of an application process estimating the amount available. Incentive funding is a competitive pool intended to reward ambitious, high-impact proposals and alignment with national strategies. Myanmar and El Salvador both won incentive funding to supplement their programs. Read more about the early applicants here.
Quarterly PSD Teleconference
3rd Annual PSD Retreat
Week of October 28
Quarterly PSD Teleconference
PSD Pre-Board Meeting
Global Fund Pre-Briefings
November 7 - 8
Global Fund 30th Board Meeting
Global Fund Fourth Replenishment & Pledging Conference
More News and Updates here.
GLOBAL FUND NEWS AND UPDATES
Board Member: Paul Schaper, Executive Director, Global Public Policy, Merck & Co.
Advisory Group Members
GBCHealth is the Focal Point for the Private Sector Delegation to the Global Fund, working with the committed companies of the Advisory Group to steer Global Fund priorities and policies, while also ensuring that the Global Fund actively engages the business sector.
For more information on how your company or private sector organization can get involved, please contact PSD Focal Point, Whitney White at email@example.com. Learn more about the Private Sector Delegation.